A Phase III Study of SCD411 in Subjects with Neovascular Age-related Macular Degeneratio

Phase 3

• Conditions: eovascular Age-related Macular Degeneration

• Registration Number: JPRN-jRCT2041210008
• Lead Sponsor: Sakamoto Taiji

Brief Summary

SCD411 is efficacious, equivalent to Eylea with respect to the change from baseline in BCVA score for study eye at Week 8. - SCD411 is well-tolerated with a favorable safety profile that is comparable with Eylea.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-16
• Study Completion: 2023-02-07
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age >=50 years.
-Active choroidal subfoveal, juxtafoveal, or extrafoveal neovascularization lesions secondary to AMD evidenced by fluorescein angiography (FA) in the study eye at screening and confirmed by the central reading center.

Exclusion Criteria

- Any prior ocular (in the study eye and fellow eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins
- Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins

Study & Design

• Study Type: Interventional
• Study Design: Not specified